#oral medication

Structure Therapeutics ने त्याच्या मौखिक GLP-1 रिसेप्टर अगोनिस्टसाठी प्रोत्साहक फेज 2 परिणाम नोंदवले आहेत, इंजेक्टेबल वजन-हानी आणि मधुमेह औषधांच्या गोळी-स्वरूपाचा विकल्प आगे केला आहे।

After years of development challenges, oral GLP-1 weight loss drugs are finally hitting the market. Novo Nordisk's oral Wegovy is already available, with Eli Lilly's orforglipron expected to win FDA approval soon.

Novo Nordisk has struck a deal with Vivtex, a biotech co-founded by MIT professor Robert Langer, to develop oral versions of obesity and diabetes treatments. The partnership could eliminate the need for weekly injections that have defined the GLP-1 drug revolution.